Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Empagliflozin for Chronic Heart Failure with Preserved Ejection Fraction Empagliflozin (Jardiance; DINAMO) Heart failure (HF) Cardiovascular System 2021 View  |  Download
Emicizumab for mild or moderate haemophilia A Emicizumab (Hemlibra) Haemophilia A Haematology 2021 View  |  Download
Emapalumab for Primary Haemophagocytic Lymphohistiocytosis Emapalumab (NI-0501; Gamifant) Primary haemophagocytic lymphohistiocytosis (HLH) Genetic Disorders , Immunology 2018 View  |  Download
Elranatamab monotherapy or with daratumumab for previously treated relapsed or refractory multiple myeloma Daratumumab (Darzalex; JNJ-54767414) , Elranatamab (PF-06863135) Multiple myeloma (MM) Haematological Cancer and Lymphomas , Skin Cancer 2024 View  |  Download
Elranatamab for treating relapsed /refractory multiple myeloma Elranatamab (PF-06863135) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2021 View  |  Download
Elotuzumab in combination with pomalidomide and low-dose dexamethasone for relapsed and refractory multiple myeloma – third line Dexamethasone (dexamethasone sodium metasulfobenzoate) , Elotuzumab (Empliciti; BMS-901608; HuLuc63) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Elinzanetant for the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with the menopause Elinzanetant Post-menopausal vasomotor symptoms Women's Health 2023 View  |  Download
Elexacaftor/tezacaftor/ivacaftor and ivacaftor for treating cystic fibrosis without an F508del mutation and with an ELX/TEZ/IVA-responsive mutation in the CFTR gene in patients aged 6 years and older Ivacaftor (Kalydeco; VX-770) , Kaftrio (fixed dose combination: Elexacaftor; Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2023 View  |  Download
Elexacaftor/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 6 to 11 years old Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor) Cystic fibrosis Genetic Disorders , Respiratory System 2019 View  |  Download
Elexacaftor/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation in patients aged 12 years old and older Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Tezacaftor (VX-661) Cystic fibrosis Genetic Disorders , Respiratory System 2020 View  |  Download
1 2 79 80 81 82 83 117 118
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications